

## July 10, 2018

The Honorable Rodney Frelinghuysen Chairman House Appropriations Committee H-305 Capitol Washington, DC 20515

The Honorable Nita Lowey Ranking Member House Appropriations Committee 1016 Longworth HOB Washington, DC 20515

The Honorable Robert Aderholt Chairman House Appropriations Subcommittee on Agriculture, Rural Development, FDA, and Related Agencies 2362A Rayburn HOB Washington, DC 20515

The Honorable Sanford Bishop Ranking Member House Appropriations Subcommittee on Agriculture, Rural Development, FDA, and Related Agencies 1016 Longworth HOB Washington, DC 20515 The Honorable Richard Shelby Chairman Senate Appropriations Committee S-128 Capitol Washington, DC 20510

The Honorable Patrick Leahy Ranking Member Senate Appropriations Committee S-128 Capitol Washington, DC 20510

The Honorable John Hoeven Chairman Senate Appropriations Subcommittee on Agriculture, Rural Development, FDA, and Related Agencies S-128 Capitol Washington, DC 20510

The Honorable Jeff Merkley Ranking Member Senate Appropriations Subcommittee on Agriculture, Rural Development, FDA, and Related Agencies S-128 Capitol Washington, DC 20510

## Submitted via electronic mail

Dear Chairmen Frelinghuysen, Shelby, Aderholt, and Hoeven, and Ranking Members Lowey, Leahy, Bishop, and Merkley:

The Alliance for a Stronger FDA thanks the House and Senate Appropriations Committees for their positive response to the FY 19 budget request for the Food and Drug Administration. Improving the resources of the FDA will have a meaningful impact on all Americans, both in FY 19 and the years to come.

The Alliance wants to ensure an FDA that is sized and modernized to meet its mandate in the 21st century. The FDA oversees products that represent 20% of consumer spending in the US and affect every American multiple times each day. Its responsibilities are global in scope and form the backbone of the world's economy. And it does all of that at a cost to each American of \$9.00 per year.

The FDA needs sufficient resources to meet its existing responsibilities, prepare for the wave of new science in medicine and food, combat the opioid epidemic and assure U.S. defensive ability against bioterrorism. Those who know the agency best—particularly regulatory professionals—are well-aware that it needs more resources to do its job properly. When the FDA is strong, America benefits.

It is the joint position of the co-signing organizations that the work done by FDA should be treated as a high priority, and that these efforts are deserving of the discretionary funding within your jurisdiction.

As you know, the Alliance for a Stronger FDA includes members from patient organizations, consumer groups and regulated industries. Some members might disagree on the specifics of how appropriations for the FDA should be spent, but we strongly agree that the FDA needs to have appropriations that enable the agency to do its job to protect the public health and ensure that the agency is working efficiently and effectively as it reviews products and implements regulatory policies.

In this appropriations cycle, House appropriators have recommended \$150 million more than the Senate. We support the higher levels of the House version, as well as the Senate's proposals for certain accounts--including critical funding for food safety that was not in the House bill and larger increases in monies for generic drugs and combating opioid abuse.

We respectfully urge you to provide robust funding that includes the higher funding levels that are proposed in the House and Senate bills and ensure that the FDA has the flexibility to use appropriations wisely. We also strongly believe that FDA needs the physical capacity to undertake its many important tasks, and therefore urge you to adopt the House level of funding provided for White Oak expansion.

We look forward to working with you as you complete the FY 2019 appropriations process and stand ready to provide any additional information you need in support of our requests.

Sincerely,

Members of the Alliance for a Stronger FDA and allied FDA stakeholders

Academy of Managed Care Pharmacy

AdvaMed

**AIDS Treatment Activists Coalition** 

AIDS Action Baltimore
The AIDS Institute

Alliance for Aging Research

Alpha-1 Foundation

American Bakers Association American Frozen Food Institute

American Red Cross

American Society for Pharmacology

& Experimental Therapeutics

American Society of Clinical Oncology American Society of Gene & Cell Therapy Association for Accessible Medicines American Society of Health-System

**Pharmacists** 

**Audentes Therapeutics** 

**Bavarian Nordic** 

**Biotechnology Innovation Organization** 

**Biotech Policy Group** 

Catalyst Healthcare Consulting Celiac Disease Foundation

Children's Cause for Cancer Advocacy

Coalition for Health Funding Consumer Federation of America

Consumer Healthcare Products Association

Council for Responsible Nutrition

Cystic Fibrosis Foundation EveryLife Foundation

FasterCures

Fight Colorectal Cancer

Friedreich's Ataxia Research Alliance

Friends of Cancer Research

Hemophilia Federation of America

HPS group

International Foundation for Alternative

Research in AIDS

International Myeloma Foundation

Johnson & Johnson

Leukemia & Lymphoma Society

Lupus and Allied Diseases Association, Inc.

Lupus Foundation of America

Mars, Incorporated

The Michael J. Fox Foundation for

Parkinson's Research

Muscular Dystrophy Association National Alliance on Mental Illness National Center for Health Research National Confectioners Association

National Consumers League National Hemophilia Foundation National Kidney Foundation

National Organization for Rare Disorders National Treasury Employees Union Personalized Medicine Coalition

Perrigo Company PLC The Pew Charitable Trusts Plastics Industry Association

Research!America Sugar Association TMJ Association U.S. Pharmacopeia